- Home
- TLSA vs ELTX Comparison
TLSA vs ELTX Comparison
Compare TLSA & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSA | ELTX |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.7M | 134.1M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | TLSA | ELTX |
|---|---|---|
| Price | $1.71 | $8.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 310.3K | 80.7K |
| Earning Date | 05-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $4.60 |
| 52 Week High | $2.60 | $12.62 |
Technical Indicators
Market Signals| Indicator | TLSA | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.99 | 51.79 |
| Support Level | $1.58 | $7.88 |
| Resistance Level | $1.75 | $8.23 |
| Average True Range (ATR) | 0.13 | 0.49 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 86.67 | 47.37 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.